Regeneron Collaborates with CytomX in Bispecific Cancer Deal

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)

Published: 21 Nov-2022

DOI: 10.3833/pdr.v2022.i11.2749     ISSN: 1756-7874

Section: Research & Development



Regeneron and CytomX Therapeutics have entered into a collaboration and licensing agreement, worth up to US$ 2 B, to develop next-generation bispecific immunotherapies for oncology indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details